Crispr Therapeutics shares tumble after significant earnings miss
Director Mark A. Paup of Northwest Bancshares, Inc. (NASDAQ:NWBI), a $1.5 billion market cap regional bank, acquired 3,500 shares of the company’s common stock on August 1, 2025. The timing appears strategic, as InvestingPro analysis indicates the stock is currently trading in oversold territory. The shares were purchased at an average price of $11.5885, with prices ranging from $11.585 to $11.5899, totaling $40,559.
Following the transaction, Paup directly owns 62,772.464 shares of Northwest Bancshares. Additionally, his spouse indirectly owns 10,261.432 shares.
In other recent news, Northwest Bancshares reported stronger-than-expected results for the second quarter of 2025. The company achieved earnings per share of $0.30, surpassing the analysts’ forecast of $0.28. Additionally, Northwest Bancshares exceeded revenue expectations with $150.38 million, compared to the projected $148.67 million. These results highlight a positive earnings surprise for the company. While the stock price saw a modest increase following the announcement, the primary focus remains on the company’s financial performance. These developments are part of the recent news surrounding Northwest Bancshares.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.